Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

1.

The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia.

Smith CC, Shah NP.

Am Soc Clin Oncol Educ Book. 2013:313-8. doi: 10.1200/EdBook_AM.2013.33.313.

PMID:
23714533
[PubMed - in process]
Free Article
2.

Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.

Sternberg DW, Licht JD.

Curr Opin Hematol. 2005 Jan;12(1):7-13. Review.

PMID:
15604885
[PubMed - indexed for MEDLINE]
3.

Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.

Swords R, Freeman C, Giles F.

Leukemia. 2012 Oct;26(10):2176-85. doi: 10.1038/leu.2012.114. Epub 2012 Apr 27. Review.

PMID:
22614177
[PubMed - indexed for MEDLINE]
4.

FLT3 mutations: biology and treatment.

Small D.

Hematology Am Soc Hematol Educ Program. 2006:178-84. Review.

PMID:
17124058
[PubMed - indexed for MEDLINE]
Free Article
5.

Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3.

Masson K, Rönnstrand L.

Cell Signal. 2009 Dec;21(12):1717-26. doi: 10.1016/j.cellsig.2009.06.002. Epub 2009 Jun 18. Review.

PMID:
19540337
[PubMed - indexed for MEDLINE]
6.

Targeting FLT3 for the treatment of leukemia.

Small D.

Semin Hematol. 2008 Jul;45(3 Suppl 2):S17-21. doi: 10.1053/j.seminhematol.2008.07.007. Review.

PMID:
18760705
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

The role of FLT3 kinase as an AML therapy target.

Beffinger M, Skwarska A.

Curr Pharm Des. 2012;18(19):2758-65. Review.

PMID:
22390761
[PubMed - indexed for MEDLINE]
8.

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.

Sattler M, Scheijen B, Weisberg E, Griffin JD.

Adv Exp Med Biol. 2003;532:121-40. Review.

PMID:
12908554
[PubMed - indexed for MEDLINE]
9.

Flt3 receptor tyrosine kinase as a drug target in leukemia.

Schmidt-Arras D, Schwäble J, Böhmer FD, Serve H.

Curr Pharm Des. 2004;10(16):1867-83. Review.

PMID:
15180525
[PubMed - indexed for MEDLINE]
10.

Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.

Moore AS, Blagg J, Linardopoulos S, Pearson AD.

Leukemia. 2010 Apr;24(4):671-8. doi: 10.1038/leu.2010.15. Epub 2010 Feb 11. Review.

PMID:
20147976
[PubMed - indexed for MEDLINE]
11.

FLT3 inhibitors: a story of the old and the new.

Fathi A, Levis M.

Curr Opin Hematol. 2011 Mar;18(2):71-6. doi: 10.1097/MOH.0b013e3283439a03. Review.

PMID:
21245757
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia.

Leung AY, Man CH, Kwong YL.

Leukemia. 2013 Feb;27(2):260-8. doi: 10.1038/leu.2012.195. Epub 2012 Jul 16. Review.

PMID:
22797419
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk